Your browser doesn't support javascript.
loading
Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine.
Casolino, R; Braconi, C; Malleo, G; Paiella, S; Bassi, C; Milella, M; Dreyer, S B; Froeling, F E M; Chang, D K; Biankin, A V; Golan, T.
Afiliación
  • Casolino R; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Bearsden, Glasgow, Scotland, UK; Department of Medicine, University and Hospital Trust of Verona, Verona, Italy.
  • Braconi C; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Bearsden, Glasgow, Scotland, UK.
  • Malleo G; Department of Surgery, University and Hospital Trust of Verona, Verona, Italy.
  • Paiella S; Department of Surgery, University and Hospital Trust of Verona, Verona, Italy.
  • Bassi C; Department of Surgery, University and Hospital Trust of Verona, Verona, Italy.
  • Milella M; Department of Medicine, Medical Oncology, University and Hospital Trust of Verona, Verona (VR), Italy.
  • Dreyer SB; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Bearsden, Glasgow, Scotland, UK; West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, UK.
  • Froeling FEM; Edinburgh Cancer Centre, Western General Hospital, NHS Lothian, Edinburgh, UK.
  • Chang DK; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Bearsden, Glasgow, Scotland, UK; West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, UK.
  • Biankin AV; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Bearsden, Glasgow, Scotland, UK; West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, UK; South Western Sydney Clinical School, Faculty of Medicine, University of NSW, Liverpool, NSW, Australia.
  • Golan T; Oncology Institute, Sheba Medical Center, Tel Hashomer, Israel.
Ann Oncol ; 32(2): 183-196, 2021 02.
Article en En | MEDLINE | ID: mdl-33248227
This review summarises the recent evidence on preoperative therapeutic strategies in pancreatic cancer and discusses the rationale for an imminent need for a personalised therapeutic approach in non-metastatic disease. The molecular diversity of pancreatic cancer and its influence on prognosis and treatment response, combined with the failure of 'all-comer' treatments to significantly impact on patient outcomes, requires a paradigm shift towards a genomic-driven approach. This is particularly important in the preoperative, potentially curable setting, where a personalised treatment allocation has the substantial potential to reduce pancreatic cancer mortality.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Medicina de Precisión Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Medicina de Precisión Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido